Puma Biotechnology, Inc.PBYINASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank69
Year-over-Year Change
Year-over-year operating cash flow growth rate
Latest
48.82%
↓ 87% vs avg
Percentile
P69
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
366.25%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 48.82% |
| Q3 2025 | -31.20% |
| Q2 2025 | 289.87% |
| Q1 2025 | -76.86% |
| Q4 2024 | 41.39% |
| Q3 2024 | 974.78% |
| Q2 2024 | -90.87% |
| Q1 2024 | 7.57% |
| Q4 2023 | -1.51% |
| Q3 2023 | 222.06% |
| Q2 2023 | 24.71% |
| Q1 2023 | -65.60% |
| Q4 2022 | -55.48% |
| Q3 2022 | 224.40% |
| Q2 2022 | 48.41% |
| Q1 2022 | -394.85% |
| Q4 2021 | -151.77% |
| Q3 2021 | 14286.49% |
| Q2 2021 | -100.47% |
| Q1 2021 | 377.92% |
| Q4 2020 | -427.62% |
| Q3 2020 | -89.40% |
| Q2 2020 | 240.62% |
| Q1 2020 | -836.91% |
| Q4 2019 | 121.43% |
| Q3 2019 | -116.51% |
| Q2 2019 | 374.83% |
| Q1 2019 | -326.76% |
| Q4 2018 | 197.77% |
| Q3 2018 | 58.83% |
| Q2 2018 | -182.06% |
| Q1 2018 | 82.44% |
| Q4 2017 | 35.15% |
| Q3 2017 | -19.59% |
| Q2 2017 | -27.38% |
| Q1 2017 | 12.01% |
| Q4 2016 | -17.40% |
| Q3 2016 | -13.25% |
| Q2 2016 | 12.04% |
| Q1 2016 | -6.05% |